SEC Comment Letter 0000000000-23-014093 to GRI Bio, Inc. (GRI)
GRI Bio, Inc.
Date: Dec. 26, 2023 · CIK: 0001824293 · Accession: 0000000000-23-014093
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276205
Letter
United States securities and exchange commission logo December 26, 2023 W. Marc Hertz, Ph.D. President and Chief Executive Officer GRI Bio, Inc. 2223 Avenida de la Playa, #208 La Jolla, CA 92037 Re:GRI Bio, Inc. Registration Statement on Form S-1 Filed December 21, 2023 File No. 333-276205 Dear W. Marc Hertz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason Miller, Esq.
Show Raw Text
United States securities and exchange commission logo
December 26, 2023
W. Marc Hertz, Ph.D.
President and Chief Executive Officer
GRI Bio, Inc.
2223 Avenida de la Playa, #208
La Jolla, CA 92037
Re:GRI Bio, Inc.
Registration Statement on Form S-1
Filed December 21, 2023
File No. 333-276205
Dear W. Marc Hertz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jason Miller, Esq.